3Miller WH Jr,Schipper HM,Lee JS, et al. Mechanisms of action of arsenic trioxide [ J ]. Cancer Res, 2002,62 ( 14 ) : 3893
4Roboz GJ, Dias S, Lam G, et al. Arsenic trioxide induces dose-and time-dependent apoptosis of endothelium and may exert on antileukemia effect via inhibition of angiogenesis [J]. Blood,2000,96(4) :1525
5Vey N, Bosly A, Guerci A, et al. Arsenic trioxide in patients with myelodysplastic syndromes: a phase Ⅱ multicenter study[J]. J Clin Oncol,2006,24(16):2465
6Schiller GJ,Slack J, Hainsworth JD, et al. phase Ⅱ multicenter study of arsenic trioxide in patients with myelodysplastic syndromes[ J]. Clin Oncol,2006,24(16) :2456
7Raza A,Buonamici S, Lisak L, et al. Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI 1 expression [J]. Leuk Res,2004,28(8) :791
8List A, Beran M, DiPersio J, et al. Opportunities for Trisenox(arsenic trioxide) in the treatment of myelodysplastic syndrome [ J ]. Leukemia, 2003,17 ( 8 ) : 1499
9Vaena DA,Walker P, Pennington K, et al. Phase Ⅱ study of low-dose topotcan in myelodysplastic syndromes: a Hoosier Oncology Group (HOG) study [ J ]. Leuk Rse, 2004, 28(1) :49
10Kantarjian H, Beran M, Cortes J, et al. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome [ J ]. Cancer, 2006,106 ( 5 ) : 1099
2Greenberg P, Cox C, LeBeau MM, et al. international scoring system for evaluating prognosis in myelodysplastic syndromes [ J ]. Blood, 1997,89(6) :2079 -2088.
3Dayyani F, Conley AP, Strom SS, et al. Cause of death in patients with lower-risk myelodysplastic syndrome [ J ]. Cancer, 2010, 116 (9) :2174 -2179.
4Guillermo GM. Myelodysplastic syndromes:2011 update on diagno- sis, risk-stratification, and management [ J ]. Am J Hemato1,2011,86 (6) :491 -498.
5Takatoku M, Uehiyama T,Okamoto S,et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload oil morbidity/mortality [ J ]. Eur J Haemato1.2007.78 (6) :487 - 494.
6Sanz G, Nomdedeu B, Such E, et al. Independent impact of iron o- verload and transfusion dependency on survival and leukemic evolu- tion in patients with myelodyspl.astic syndrome [ J ]. Blood, 2008, 112:640.
7Greenberg PL, Attar E, Bennett JM, et al. NCCN Clinical Practice Guidelines in Oncology:myelodysplastic syndromes[ J]. J Natl Corn-pr Cane Netw,2011,9(1) :30 -56.
9Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes:Results of six cross- sectional physician surveys [ J]. J Natl Cancer Inst, 2008, 100 (21) :1542 - 1551.
10Moyo V, Lefebvre P, Duh MS, et al. Erythropoiesis-stimulating a- gents in the treatment of anemia in myelodysplastic syndromes : A meta-analysis [ J ]. Ann Hemato1,2008,87 (7) :527 - 536.
